Liste des publications scientifiques du CHU de Clermont-Ferrand

Cette liste prend en compte l'ensemble des publications scientifiques du CHU référencées sur PubMed de 1973 au 31.12.2020

Auteurs : Pautier, P; Penel, N; Ray-Coquard, I; Chenuc, G; Duffaud, F ; et al.

Revue : European journal of cancer (Oxford, England : 1990) - ISSN : 1879-0852 - NLMID : 9005373
Date de Publication : Janvier 2020
Vol. : 125 Pages : 31-37


Résumé : Options in second-line therapy after doxorubicin-based chemotherapy for metastatic/advanced leiomyosarcoma include gemcitabine (G), trabectedin and pazopanib (P) monotherapy. Currently, no combination therapy is better than monotherapy. LMS03 is an open-label multicentre single-group phase II study designed to assess the efficacy and tolerance of G + P in the second-line setting.Patients (pts), ECOG ?2, with metastatic leiomyosarcomas (LMS) after first-line doxorubicin chemotherapy failure were eligible. Pts were treated with G 1000 mg/m2 on days 1 and 8 of each 21 days (maximum eight cycles), in combination with oral daily P (800 mg), until disease progression/toxicity. 9-month progression-free survival (PFS) rate was the primary endpoint. Inacceptable and promising 9-month PFS rates were defined, in the intent-to-treat population, as 32% and 44%.106 pts were included with a mean age of 59.8 years and an ECOG 0 in 63.5%; the primary tumour site was uterus in 61%. Pts were treated with P + G for a median of 3.8 mo, and P for a median of 4.2 mo. The 9-month PFS rate was 32.1% (95% CI 23.1-41.1). After a median follow-up of 14.2 months, the PFS was 6.5 months (95% CI 5.6-8.2), and the overall survival was 22.4 months (95% CI 16.9-26.5). The best response was 23.8%. The most frequent reported grade 3-4 adverse events were haematological.LMS03 failed to show that second-line therapy, with gemcitabine combined with pazopanib, followed by pazopanib alone, was beneficial for advanced LMS patients. Eudract N°2011-001308-36 and NCT01442662.

Mesh : Adult|Aged|Aged, 80 and over|Antimetabolites, Antineoplastic|Antineoplastic Combined Chemotherapy Protocols/pharmacology/therapeutic use|Deoxycytidine/analogs & derivatives/pharmacology/therapeutic use|Female|Humans|Leiomyosarcoma/drug therapy|Male|Middle Aged|Pyrimidines/pharmacology/therapeutic use|Sulfonamides/pharmacology/therapeutic use

Mots clés auteurs : /Chemotherapy/Leiomyosarcoma/Maintenance therapy/Metastatic disease/Pazopanib

Auteurs : Gouëffic, Y; Sauguet, A; Desgranges, P; Hoffmann, CT; Maurel, B ; et al.

Revue : JACC. Cardiovascular interventions - ISSN : 1876-7605 - NLMID : 101467004
Date de Publication : Février 2020
Vol. : 13 Numéro 4 Pages : 447-457


Résumé : The primary objective of the BATTLE (Bare Metal Stent vs. Paclitaxel Eluting Stent in the Setting of Primary Stenting of Intermediate-Length Femoropopliteal Lesions) trial is to demonstrate the clinical superiority of the Zilver PTX stent over the Misago stent in the treatment of femoropopliteal lesions.No randomized studies have compared self-expanding paclitaxel-eluting stents with bare-metal stents in the treatment of femoropopliteal lesions.BATTLE is a multicenter randomized controlled trial in patients with symptomatic (Rutherford category 2 to 5) de novo lesions of the superficial femoral or proximal popliteal artery. The primary endpoint is freedom from in-stent restenosis (ISR) at 1 year, with restenosis defined as a peak systolic velocity index >2.4 at the target lesion. The Kaplan-Meier method was used to evaluate time-to-event data for freedom from ISR over the 2-year follow-up period.Between March 2014 and August 2016, 186 patients were enrolled; 91 were assigned to the Misago arm and 90 to the Zilver PTX arm. Kaplan-Meier 1-year estimates of freedom from ISR were 88.6% for Misago and 91% for Zilver PTX (hazard ratio [HR]: 1.2; 95% confidence interval [CI]: 0.6 to 2.4; p = 0.64). Comparing Misago with Zilver PTX, 2-year estimates were 6.4% and 1.2% (HR: 7.3; 95% CI: 0.9 to 59.3; p = 0.0632) for mortality, 74.6% and 78.8% (HR: 1.2; 95% CI: 0.6 to 2.1; p = 0.62) for patency, and 14.4% and 12.4% (HR: 1.2; 95% CI: 0.5 to 2.8; p = 0.69) for target lesion revascularization.In the treatment of symptomatic femoropopliteal lesions, the Zilver PTX stent failed to show superiority over the Misago stent in freedom from ISR at 1 year.

Mesh : Aged|Aged, 80 and over|Cardiovascular Agents/administration & dosage/adverse effects|Drug-Eluting Stents|Endovascular Procedures/adverse effects/instrumentation/mortality|Female|Femoral Artery/diagnostic imaging/physiopathology|France|Humans|Male|Metals|Middle Aged|Paclitaxel/administration & dosage/adverse effects|Peripheral Arterial Disease/diagnostic imaging/mortality/physiopathology/therapy|Popliteal Artery/diagnostic imaging/physiopathology|Prospective Studies|Prosthesis Design|Recurrence|Risk Factors|Stents|Time Factors|Treatment Outcome|Vascular Patency

Mots clés auteurs : /Misago/Zilver PTX/femoropopliteal/paclitaxel/restenosis

Auteurs : Burel-Vandenbos, F; Pierron, G; Thomas, C; Hasselblatt, M; Godfraind, C ; et al.

Revue : Neuropathology and applied neurobiology - ISSN : 1365-2990 - NLMID : 7609829
Date de Publication : Août 2020
Vol. : 46 Numéro 5 Pages : 506-509
Auteurs : Leger, T; Jouve, C; Patrac, V; Demaison, L; Azarnoush, K ; et al.

Revue : Free radical biology & medicine - ISSN : 1873-4596 - NLMID : 8709159
Date de Publication : Juin 2020
Vol. : 153 Pages : 71-79


Résumé : Evaluating the activity of cardiac mitochondria is probably the best way to estimate early cellular damage in chronic pathology. Early diagnosis allows rapid therapeutic intervention thus increasing patient survival rate in a number of diseases. However, data on human cardiac mitochondria are scarce in the international literature. Here, we describe a method to extract and study functional mitochondria from the small-sized right atrial aliquots (minimum of 400 mg) obtained during extracorporeal circulation and usually considered as surgical waste products. The mitochondria were purified through several mechanical processes (fine myocardial cutting, tissue grinding and potter Elvehjem homogenising), an enzymatic proteolytic action (subtilisin) and differential centrifugations. In chronic pathologies, including obesity, early disturbances of mitochondrial function can occur. The effects of obesity on the rate of mitochondrial oxygen consumption and H2O2 release were thus determined with three different substrates (glutamate/malate, succinate/rotenone and palmitoylcarnitine/malate). The human atrial mitochondria were of high quality from a functional viewpoint, compared to rat ventricle organelles, but the extraction yield of the human mitochondria was twice lower than that of rat mitochondria. Tests showed that glutamate/malate-related ADP-stimulated respiration was strongly increased in obese subjects, although the oxidation of the other two substrates was unaffected. Reactive oxygen species (ROS) production by the isolated mitochondria was low in comparison with that of the lean subjects. These results confirm those found in one of our previous studies in the ventricles of rats fed a high-fat diet. In conclusion, the described method is simple, reliable and sensitive. It allows for the description of the impact of obesity on the function of atrial mitochondria while using only a small patient sampling (n = 5 in both the lean and the obese groups).

Mots clés auteurs : /Human right atrium/Mitochondria/Obesity/Oxidative phosphorylation/ROS

Auteurs : Atallah, S; Casiraghi, O; Fakhry, N; Aupérin, A; Baujat, B ; et al.

Revue : European journal of cancer (Oxford, England : 1990) - ISSN : 1879-0852 - NLMID : 9005373
Date de Publication : Mai 2020
Vol. : 130 Pages : 241-249


Résumé : Adenoid cystic carcinoma (ACC) accounts for 1% of malignant head and neck tumours [1] and 10% of salivary glands malignant tumours. The main objective of our study is to investigate the prognostic factors influencing the event-free survival (EFS) of patients with ACC.A multicentre prospective study was conducted from 2009 to 2018. All 470 patients with ACC whose survival data appear in the REFCOR database were included in the study. The main judgement criterion was EFS. Both a bivariate survival analysis using log-rank test and a multivariate using Cox model were performed using the R software.Average age was 55 years. Females accounted for 59.4% of the cohort. The body mass index (BMI) was normal in 86% of cases. Tumours were located in minor salivary glands in 60% of cases. T3/T4 stages represented 58%; 89% of patients were cN0. histological grade III was observed on 21% of patients. The EFS and overall 5-year survival rates were 50% and 85%, respectively. After adjustment, the most significant pejorative prognostic factors were age ?65 years (hazard ratio [HR] = 1.67), BMI<16.5 (HR = 2.62), and lymph node invasion cN (HR = 2.08).Age, BMI and N stage are the three main clinical prognostic factors determining EFS identified in this prospective series of patients with ACC. Such findings open new research perspectives on the influence of these components on initial patient care.

Mesh : Adolescent|Adult|Aged|Aged, 80 and over|Carcinoma, Adenoid Cystic/diagnosis/epidemiology/pathology/therapy|Cohort Studies|Disease Progression|Female|France/epidemiology|Head and Neck Neoplasms/diagnosis/epidemiology/pathology/therapy|Humans|Male|Middle Aged|Prognosis|Progression-Free Survival|Prospective Studies|Risk Factors|Salivary Gland Neoplasms/diagnosis/epidemiology/pathology/therapy|Survival Analysis|Young Adult

Mots clés auteurs : /Adenoid cystic carcinoma/Event-free survival/Prognostic factors/REFCOR

Pages